Back to results
US 2026/0265227 A1Published application
Amide prodrugs and uses thereof
AssigneeAutobahn Therapeutics, Inc.
InventorsJason Randall HARRIS, Jill Melissa BACCEI, Brian Andrew STEARNS
Life of this patent
Estimating the term…
Abstract
Described herein are fatty acid amide hydrolase (FAAH) cleavable prodrugs of compounds that modulate sphingosine-1-phosphate receptor 5 (S1P5), methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds and methods of using such compounds in treating a CNS disease or disorder.
Claims37
A compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof:
- wherein:
- R1 is selected from hydrogen, —OR7, —NR7R8, C1-C6alkyl, C2-C6lkenyl, C2-C6alkynyl, C3-C6cycloalkyl, C2-C6heterocycloalkyl, C1-9heteroaryl, phenyl, and —C1-C6alkyl-phenyl, wherein C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, C2-C9heterocycloalkyl, C1-9heteroaryl, phenyl, and —C1-C6alkyl-phenyl are optionally substituted with one or more groups selected from halogen, C1-C6alkyl, C1-6 haloalkyl, C3-C6cycloalkyl, —CN, —OR10, —N(R10)(R11), and —S(O)2R13;
- R2 is selected from hydrogen, —OR7, —NR7R8, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, C2-C6heterocycloalkyl, C1-9heteroaryl, phenyl, and —C1-C6alkyl-phenyl, wherein C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, C2-C9heterocycloalkyl, C1-9heteroaryl, phenyl, and —C1-C6alkyl-phenyl are optionally substituted with one or more groups selected from halogen, C1-C6alkyl, C1-6 haloalkyl, C3-C6cycloalkyl, —CN, —OR10, —N(R10)(R11), and —S(O)2R13;
- or R1 and R2 are combined to form a C2-C9heterocycloalkyl optionally substituted with one or more groups selected from halogen, C1-6alkyl, C1-6haloalkyl, —OR10, —N(R10)(R11), and —S(O)2R13;
- R3 is selected from halogen, —CN, C1-6alkyl, C1-6haloalkyl, C2-6alkenyl, C2-6alkynyl, —OR10, —SR10, —N(R10)(R11), —C(O)R13, —S(O)2R13, and —S(O)2N(R10)(R11)—, wherein C1-6 alkyl, C2-6alkenyl, and C2-6alkynyl, are optionally substituted with one, two, or three groups selected from halogen, C1-6alkyl, C1-6haloalkyl, —OR10, —N(R10)(R11), and —C(O)OR10;
- each R4 is independently selected from halogen, —CN, C1-6alkyl, C1-6haloalkyl, C2-6 alkenyl, C2-6alkynyl, C3-6cycloalkyl, C2-9heterocycloalkyl, C6-10aryl, C1-9heteroaryl, —OR10, —SR10, —N(R10)(R11), —C(O)OR10, —OC(O)N(R10)(R11), —N(R12)C(O)N(R10)(R11), —N(R12) C(O)OR13, —N(R12)S(O)2R13, —C(O)R13, —S(O)R13, —OC(O)R13, —C(O)N(R10)(R11), —C(O)C(O)N(R10)(R11), —N(R12)C(O)R13, —S(O)2R13, —S(O)2N(R10)(R11)—, —S(═O)(═NH)N(R10)(R11), —CH2C(O)N(R10)(R11), —CH2N(R12)C(O)R13, —CH2S(O)2R13, and —CH2S(0)2N(R10)(R11), wherein C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, C2-9heterocycloalkyl, C6-10aryl, and C1-9 heteroaryl are optionally substituted with one, two, or three groups selected from halogen, C1-6alkyl, C1-6haloalkyl, —OR10, —N(R10)(R11), and —C(O)OR10,
- R5 and R6 are independently selected from hydrogen and C1-C6alkyl;
- each R7 and each R8 are independently selected from hydrogen and C1-C6alkyl;
- R9a and R9b are independently selected from hydrogen, halogen, —CN, C1-6alkyl, C1-6 haloalkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, C2-9heterocycloalkyl, C6-10aryl, C1-9heteroaryl, —OR10, —SR10, —N(R10)(R11), wherein C1-6alkyl, C2-6alkenyl, C2-6 alkynyl, C3-6cycloalkyl, C2-9heterocycloalkyl, C6-10aryl, and C1-9heteroaryl are optionally substituted with one, two, or three groups selected from halogen, C1-6alkyl, C1-6haloalkyl, —OR10, —N(R10)(R11), and —C(O)OR10;
- each R10 is independently selected from hydrogen, C1-6alkyl, C1-6 haloalkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, —C1-6alkyl-C3-6cycloalkyl, C2-9heterocycloalkyl, —C1-6 alkyl-C2-9heterocycloalkyl, C6-10aryl, —C1-6alkyl-C6-10aryl, C1-9heteroaryl, and —C1-6 alkyl-C1-9heteroaryl, wherein C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, —C1-6 alkyl-C3-6cycloalkyl, C2-9heterocycloalkyl, —C1-6alkyl-C2-9heterocycloalkyl, C6-10aryl, —C1-6alkyl-C6-10aryl, C1-9heteroaryl, and —C1-6alkyl-C1-9heteroaryl are optionally substituted with one, two, or three groups selected from halogen, —CN, hydroxy, C1-6 alkyl, C1-6haloalkyl, C1-6alkoxy, C3-6cycloalkyl, C2-9heterocycloalkyl, C6-10aryl, and C1-9heteroaryl;
- each R11 is independently selected from hydrogen, C1-6alkyl, and C1-6haloalkyl;
- each R12 is independently selected from hydrogen, C1-6alkyl, and C1-6haloalkyl;
- each R13 is independently selected C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, C2-9 heterocycloalkyl, C6-10aryl, and C1-9heteroaryl, wherein C1-6alkyl, C2-6alkenyl, C2-6 alkynyl, C3-6cycloalkyl, C2-9heterocycloalkyl, C6-10aryl, and C1-9heteroaryl are optionally substituted with one, two, or three groups selected from halogen, —CN, hydroxy, C1-6alkyl, C1-6haloalkyl, C1-6alkoxy, C3-6cycloalkyl, C2-9heterocycloalkyl, C6-10aryl, and C1-9heteroaryl;
- and
- m is 0, 1, 2, or 3.
12 more elements
A compound selected from:
- or a pharmaceutically acceptable salt or solvate thereof.
A compound selected from:
- or a pharmaceutically acceptable salt or solvate thereof.
Dependencies are inferred from the claim text.